STING1 and neoplasm: Given the ubiquity of radiotherapy in cancer care, the complex interactions of these therapies with a tumor microenvironment that has been remodeled by radiation should be considered, lest STING activation inadvertently contribute to immune suppression and radioresistance, as shown by Deng et al. (16).